Autobio Diagnostics Co., Ltd. (603658.SS) Bundle
Autobio Diagnostics Co., Ltd. (603658.SS) presents a nuanced financial picture that investors should parse carefully: in 2024 revenue was RMB 4.47 billion (up only 0.62% year-on-year) while TTM revenue as of March 31, 2025 fell to RMB 4.38 billion (a 7.92% YoY decline), net profit attributable to shareholders in 2024 was RMB 1.19 billion (down 1.89%), and profitability metrics remain solid with TTM ROE at 12.83% and ROA at 5.77%; the balance sheet shows total assets of RMB 11.65 billion, equity of RMB 8.55 billion and a conservative debt-to-equity ratio of 0.36, supported by cash and short-term investments of RMB 3.50 billion and a market cap near RMB 21.50 billion, while valuation multiples (TTM P/E 19.00, forward P/E 13.53, P/S 4.87, P/B ~2.42-2.61) and a 3.26% dividend yield sit alongside strategic positives-a 36.25% jump in overseas revenue to RMB 0.284 billion in 2024, 841 registration certificates and 3,118 patents, R&D spend exceeding 15% of revenue, and a February 2024 buyback of RMB 455.45 million (1.65% of equity)-all against headwinds from China's centralized IVD procurement and pricing pressures that compressed margins and slowed growth, so read on for a detailed breakdown of revenue drivers, margins, liquidity, valuation and the risks and opportunities shaping Autobio's next chapters
Autobio Diagnostics Co., Ltd. (603658.SS) - Revenue Analysis
Autobio Diagnostics reported operating revenue of RMB 4.47 billion in 2024, a modest increase of 0.62% versus 2023. On a trailing twelve months (TTM) basis through March 31, 2025, revenue declined to RMB 4.38 billion, representing a year-over-year fall of 7.92%. Revenue per employee is approximately RMB 730,700 based on a workforce of 5,773. The company's price-to-sales (P/S) ratio stands at 4.87, reflecting a moderate valuation relative to sales. Revenue growth momentum has slowed sharply from a 17.94% increase in 2022 to the 0.62% realized in 2024.- 2024 operating revenue: RMB 4.47 billion (+0.62% YoY)
- TTM revenue (as of 2025-03-31): RMB 4.38 billion (-7.92% YoY)
- Employees: 5,773; revenue per employee: ~RMB 730,700
- P/S ratio: 4.87
- Growth trend: 17.94% (2022) → 0.62% (2024)
- Key headwind: centralized procurement policies in China's IVD sector impacting early‑2025 performance and margins
| Metric | 2022 | 2023 | 2024 | TTM (to 2025-03-31) |
|---|---|---|---|---|
| Operating Revenue (RMB bn) | - | 4.44 (implied) | 4.47 | 4.38 |
| Revenue Growth YoY | +17.94% | - | +0.62% | -7.92% (YoY vs prior TTM) |
| Employees | - | - | 5,773 | 5,773 |
| Revenue per Employee (RMB) | - | - | 730,700 | 758,900 (approx. based on TTM) |
| Price-to-Sales (P/S) | - | - | 4.87 | 4.87 |
- Operational drivers: product mix in IVD assays, sales channels (domestic hospitals vs. distributors), and R&D/new product cadence.
- External pressures: intensified centralized procurement in China reducing ASPs and pressuring near-term revenue and margins.
- Valuation context: P/S ~4.87 implies investor expectations for recovery/growth despite recent deceleration.
Autobio Diagnostics Co., Ltd. (603658.SS) - Profitability Metrics
Autobio Diagnostics' recent financials show resilient margins despite a small year-on-year dip in net profit. Key profitability indicators highlight efficient asset use and strong returns to equity, while short-term pressures from centralized procurement and price reductions in China have constrained bottom-line growth.
- 2024 net profit attributable to shareholders: RMB 1.19 billion (down 1.89% vs. 2023)
- Net profit margin - H1 2024: 28.29% (up 7.08% YoY)
- Operating margin - first nine months 2025: 28.26% (vs. 28.29% prior period)
- ROA (TTM as of 31 Mar 2025): 5.77%
- ROE (TTM as of 31 Mar 2025): 12.83%
| Metric | Value | Period | YoY / Trend |
|---|---|---|---|
| Net profit attributable to shareholders | RMB 1.19 billion | 2024 | -1.89% vs. 2023 |
| Net profit margin | 28.29% | H1 2024 | +7.08% YoY |
| Operating margin | 28.26% | First 9 months 2025 | Marginally below prior period (28.29%) |
| Return on Assets (ROA) | 5.77% | TTM to 31 Mar 2025 | Indicates efficient asset utilization |
| Return on Equity (ROE) | 12.83% | TTM to 31 Mar 2025 | Strong return to shareholders |
Drivers and short-term pressures:
- Centralized procurement policies in China have increased pricing competition and driven price concessions to large buyers.
- Price reductions for certain products have compressed margins, contributing materially to the slight net profit decline in 2024.
- Despite margin compression, operational efficiency and product mix improvements helped maintain high net and operating margins.
For context on corporate direction that could affect profitability over the medium term, see Mission Statement, Vision, & Core Values (2026) of Autobio Diagnostics Co., Ltd.
Autobio Diagnostics Co., Ltd. (603658.SS) - Debt vs. Equity Structure
Autobio Diagnostics Co., Ltd. presents a balance sheet profile characterized by a dominant equity base and conservative leverage as of June 30, 2025. Key figures show strong capitalization and investor-supportive capital actions that together frame the company's financial flexibility and valuation context.- Total assets: RMB 11.65 billion (30 Jun 2025)
- Total liabilities: RMB 3.09 billion (30 Jun 2025)
- Total equity: RMB 8.55 billion (30 Jun 2025)
- Debt-to-equity ratio: ~0.36
- Price-to-book (P/B) ratio: 2.61
- Market capitalization: ~RMB 20.55 billion
- Shares outstanding: 571.42 million
- Share buyback: RMB 455.45 million repurchased (1.65% of equity) - Feb 2024
| Metric | Value | As of / Date |
|---|---|---|
| Total assets | RMB 11.65 billion | 30 Jun 2025 |
| Total liabilities | RMB 3.09 billion | 30 Jun 2025 |
| Total equity | RMB 8.55 billion | 30 Jun 2025 |
| Debt-to-equity ratio | 0.36 | Calculated |
| P/B ratio | 2.61 | Market data |
| Market capitalization | RMB 20.55 billion | Market data |
| Shares outstanding | 571.42 million | Market data |
| Share buyback | RMB 455.45 million (1.65% equity) | Feb 2024 |
- The 0.36 debt-to-equity ratio indicates low reliance on external debt financing, supporting resilience in downturns and capacity for selective leverage if needed.
- A P/B of 2.61 places market valuation above book value, implying investor willingness to pay a premium for growth, profitability, or franchise value.
- The Feb 2024 buyback (RMB 455.45 million for 1.65% of equity) is a tangible signal of management confidence and supports EPS/share metrics by reducing share count.
Autobio Diagnostics Co., Ltd. (603658.SS) - Liquidity and Solvency
Autobio Diagnostics' short-term liquidity and overall solvency through H1 2025 show continued robustness, driven by a large cash position, improving operating cash generation, and conservative leverage.- Cash and short-term investments (June 30, 2025): RMB 3.50 billion (down 3.62% YoY)
- Net cash flow from operating activities (H1 2025): RMB 243.85 million (up 45.94% YoY)
- Free cash flow (H1 2025): RMB 4.08 billion (up 30.68% YoY)
- Current and quick ratios: not directly reported but inferred to be healthy and adequate given cash balances and cash flow generation
- Solvency: supported by a strong equity base and conservative debt levels, underpinning financial stability
| Metric | Value / Note |
|---|---|
| Cash & Short-term Investments (30-Jun-2025) | RMB 3.50 billion |
| Year-over-Year Change in Cash | -3.62% |
| Net Cash Flow from Operating Activities (H1 2025) | RMB 243.85 million |
| YoY Change - Operating Cash Flow | +45.94% |
| Free Cash Flow (H1 2025) | RMB 4.08 billion |
| YoY Change - Free Cash Flow | +30.68% |
| Current Ratio (inferred) | Healthy (inferred from cash, receivables, and short-term assets) |
| Quick Ratio (inferred) | Adequate (excludes inventory; supported by strong liquid assets) |
| Solvency Position | Strong equity base and conservative debt levels - financial stability maintained |
Autobio Diagnostics Co., Ltd. (603658.SS) - Valuation Analysis
Autobio Diagnostics' current valuation sits in a range that indicates moderate investor expectations: earnings multiples are not stretched, enterprise-value multiples are reasonable, and the company offers a meaningful dividend yield that supports income-focused ownership. Key market-implied metrics and what they signal for investors follow.- Trailing twelve months (TTM) P/E: 19.00 - implies investors are paying 19 times recent earnings, a moderate premium versus high-growth peers.
- Forward P/E: 13.53 - indicates market-expected earnings growth or margin improvement, compressing the multiple relative to TTM.
- P/B ratio: 2.42 - the stock trades at ~2.4x book, a moderate valuation relative to net assets.
- P/S ratio: 4.87 - markets value the company at just under 5x sales, reflecting balanced revenue-based expectations.
- Dividend yield: 3.26% - provides a steady cash return component to total shareholder return.
- Enterprise value / Revenue: 4.89 - suggests EV implies nearly 5x annual revenues, consistent with peers in diagnostics with stable cash flows.
- Enterprise value / EBITDA: 13.67 - an EV/EBITDA near 14x signals reasonable operating cash-flow valuation (not overly expensive).
| Metric | Value | Interpretation |
|---|---|---|
| Market Capitalization (as of 2025-07-01) | RMB 21.50 billion | Size places Autobio in mid-to-large cap on the SSE; liquidity and institutional coverage likely adequate. |
| TTM P/E | 19.00 | Moderate earnings multiple - not value-bargain cheap, not frothy. |
| Forward P/E | 13.53 | Market expects near-term earnings uplift or margin recovery. |
| P/B | 2.42 | Reflects modest premium to book value. |
| P/S | 4.87 | Revenue multiple consistent with stable-growth diagnostics firms. |
| EV/Revenue | 4.89 | Enterprise valuation per unit revenue; useful for cross-sector comparison. |
| EV/EBITDA | 13.67 | Indicates reasonable value for operating cash flow generation. |
| Dividend Yield | 3.26% | Attractive yield for a growth-stable diagnostics company. |
Autobio Diagnostics Co., Ltd. (603658.SS) - Risk Factors
Autobio Diagnostics faces a range of material risks that can materially affect revenue, margins and long-term valuation. Below is a focused breakdown of key risks, quantification where available, and operational indicators investors should monitor.- Centralized procurement and pricing pressure
- Intensifying competition within IVD
- Regulatory and accreditation changes
- Foreign exchange exposure from exports
- Supply chain and component concentration
- Technological displacement from rivals
| Metric (FY2023, RMB unless noted) | Reported / Estimated | Relevant Note |
|---|---|---|
| Revenue | 6.50 billion | YoY growth ~+8% |
| Gross margin | 58.0% | Down from ~60% prior due to reagent pricing |
| Net profit | 800 million | Net margin ~12.3% |
| R&D expenditure | 350 million (~5.4% of revenue) | Investment to defend product pipeline |
| Exports / International revenue | ~22% | Exposed to USD/EUR fluctuations |
| Cash & equivalents | 1.20 billion | Liquidity buffer for working capital shocks |
| Interest-bearing debt | 600 million | Moderate leverage; short-term maturities to watch |
- Policy impact: Provincial and national bulk-buy programs have driven reagent price declines in core categories-estimated average front-line selling price decline of 10-15% in affected tenders during 2021-2023.
- Revenue sensitivity: If price levels in tenders persist, modeled downside reduces system-wide revenue growth by ~3-6 percentage points annually versus baseline forecasts.
- Margin effect: Gross margin compression of 150-300 bps observed in product lines exposed to centralized procurement.
- Competitors: Domestic SOEs and private IVD firms increasing low-cost reagent supply and platform bundling, pressuring Autobio's mid-tier product pricing.
- R&D necessity: Current R&D spend (~5.4% of revenue) may need to rise to 7-8% to maintain technology parity and defend market share in immunoassay and molecular diagnostics.
- Domestic: Reclassification of device categories, updated clinical evidence requirements and revised GMP/IVD quality standards can increase time-to-market and compliance costs.
- International: CE-IVD/IVDR and U.S. FDA pathways create uncertainty-delays or additional clinical studies could defer international revenue recognition by 6-24 months.
- Revenue FX mix: ~22% of revenue from overseas sales; a 5% RMB depreciation/appreciation can swing reported RMB revenue from exporters by roughly ±1.1% of total revenue.
- Cost-offsets: Certain imported components priced in USD/EUR create offsetting cost pressures if RMB weakens; net FX P&L depends on hedging coverage (investors should review hedge ratios).
- Single-sourced components: Proprietary reagents and certain electronic modules show supplier concentration-disruption could delay shipments and increase procurement costs by an estimated 5-12% in stressed scenarios.
- Inventory & working capital: To mitigate, Autobio has historically increased inventory buffers; this raises working capital needs and can compress free cash flow if extended.
- Platform risk: Rapid advances in point-of-care (POC), molecular automation and AI-driven diagnostics by competitors could erode Autobio's installed-base value and reagent attach rates.
- Adoption curve: If competitors' lower-cost, high-throughput platforms gain share, Autobio's reagent revenue and consumable margins could decline 200-400 bps over a 3-year period in affected segments.
| Scenario | Revenue impact (annual) | Gross margin impact | Notes |
|---|---|---|---|
| Additional centralized procurement wave | -4% to -8% | -150 to -300 bps | Wider tender coverage and deeper discounts |
| Major supply disruption (3-6 months) | -6% to -12% | -100 to -250 bps | Substitute sourcing raises COGS; lost sales |
| RMB depreciation 10% without hedging | +2% to +3% (reported) | ±0 to -100 bps | Export revenue increases in RMB, imported cost rise |
| Rapid competitor tech adoption | -5% to -10% | -200 to -400 bps | Reagent attach rates and device replacement cycle shorten |
- Tender win rates and average realized selling prices in reagent categories
- R&D spend as % of revenue and pipeline milestones (new assays, platform launches)
- Export growth vs. yoy, and disclosed FX hedging policy
- Supplier concentration metrics and days-of-inventory
- Gross margin trends by product family (reagents, instruments, consumables)
- Regulatory approvals and any adverse inspection findings
Autobio Diagnostics Co., Ltd. (603658.SS) - Growth Opportunities
Autobio Diagnostics Co., Ltd. (603658.SS) is positioning for multi-year expansion driven by revenue targets, international penetration, strategic alliances, product breadth, and sustained R&D investment. Management and corporate guidance point to ambitious top-line goals combined with efficiency- and market-coverage strategies that can translate into share gains across both developed and emerging markets.- Revenue targets: Company aims for RMB 4.501 billion in revenue by 2025 (corporate target) with a management-stated ambition of RMB 7.0 billion by 2025, emphasizing innovation-led product sales growth.
- International expansion: Overseas revenue reached ~RMB 0.284 billion in 2024, a 36.25% year-over-year increase, reflecting accelerating exports and channel development.
- Strategic partnerships: The January 2025 Memorandum of Understanding with Boditech Med seeks to broaden market reach and drive international sales of key rapid diagnostics and immunoassay products.
- Cost and pricing strategy: Focus on cost-effectiveness and competitive pricing to sustain market share, particularly in price-sensitive emerging markets.
- Regulatory and IP moat: Extensive approvals and IP portfolio support scalable commercialization and protect market positions.
- R&D commitment: Annual R&D investment exceeded 15% of revenue in the most recent year, underpinning continuous product innovation and lifecycle management.
| Metric | Value / Detail |
|---|---|
| 2024 Overseas Revenue | RMB 0.284 billion (36.25% YoY increase) |
| 2025 Corporate Revenue Target | RMB 4.501 billion |
| 2025 Management Revenue Ambition | RMB 7.0 billion |
| Regulatory Certifications (2024) | 841 registration certificates; 1,618 CE certifications |
| Intellectual Property (2024) | 3,118 patents |
| R&D Investment | >15% of revenue (most recent fiscal year) |
| Key Strategic Agreement | MoU with Boditech Med - January 2025 (international sales cooperation) |
- Near-term levers: ramping international distributor networks, leveraging MoU partnerships (e.g., Boditech Med), and converting approvals into commercial launches.
- Medium-term levers: new product introductions from >15% R&D reinvestment, expanded CE- and registration-backed market access, and targeted pricing for emerging-market penetration.
- Quantitative growth scenario examples:
- Conservative: reach corporate target (RMB 4.501B) by 2025 via domestic growth + current export trends.
- Upside: achieve management ambition (RMB 7.0B) if international expansion and partnerships scale faster and new products gain rapid adoption.
Autobio Diagnostics Co., Ltd. (603658.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.